Pay in 4 interest-free payments of $7.18 Learn more
Ships within 48 hours · Estimated delivery Aug 1 - Aug 6
Dispose of the needle immediately in your NHS-provided sharps container
Retatrutide (LY3437943) is a peptide developed by Eli Lilly that acts on three different metabolic receptors simultaneously: GLP-1 receptor GIP receptor Glucagon receptor This makes Retatrutide the first triple-agonist peptide to reach advanced Phase 3 clinical development
While weight loss with GLP-1 receptor agonists prior to IVF remains a controversial topic, as a weight loss specialist, I continue to work with patients and my reproductive medicine colleagues to meet patients goals as they relate to weight and fertility. Despite the possible benefits these medications may have on fertility, more research is needed because the medications are still new
Factors such as BMI , metabolism, diet, and activity levels all influence the pace of results
Risk of stability and dosing accuracy GLP-1 receptor agonist medications are typically available in pre-filled injection form to deliver a precise dose
US$ 23.82
US$ 20.06
US$ 27.90
